Here’s what everyone’s missing about Ozempic, Wegovy, and their competitors reshaping entire industries: the disruption isn’t happening at the speed or scale anyone predicted.
It’s not because the drugs don’t work. They do—spectacularly. Weight loss of 15-22% in real patients is genuinely transformative. The problem is that Wall Street built elaborate bear cases around a false assumption: that GLP-1 adoption would race toward 40% of the eligible population, triggering dominoes across food companies, airlines, and medical device makers like some perfectly choreographed financial apocalypse.
That’s not what’s happening. And if you’re building an investment thesis, the gap between the narrative and reality is where the real money lives.
The Truth Hiding in Earnings Call Transcripts
When you stop reading analyst reports and actually pull the earnings calls—ResMed, Inspire Medical, Dexcom, PepsiCo, Yum Brands—something unexpected emerges. Companies aren’t reporting GLP-1 revenue cliffs. They’re reporting strategy adjustments.
Take ResMed, the sleep-apnea device giant that supposedly should’ve gotten hammered as GLP-1 users shed weight and stopped needing CPAP machines. The company’s Q2 FY2026 call included actual data: GLP-1 patients were 10-11% more likely to initiate CPAP therapy and 6% more likely to continue resupply. Double-digit revenue growth continued.
Why? Because the people losing weight aren’t the ones with severe sleep apnea. The patient populations don’t cleanly overlap. And even when they do, weight loss sometimes makes people more likely to seek medical attention as their baseline health improves and they become aware of remaining issues.
This is the kind of detail that kills narratives. And it’s everywhere if you look.
Inspire Medical—a company that literally makes implants for sleep apnea—was explicit in their Q1 2026 transcript about modeling GLP-1 as a future revenue headwind. That’s real risk. But notice: they’re modeling it as a future effect, not a current one. They’re preparing defensively, not reacting to present collapse.
Dexcom, the continuous glucose monitor company, framed GLP-1 adoption differently still. Instead of seeing it as a threat to their T2 diabetes monitoring business, they called it a tailwind. Why? Patients on GLP-1s need more monitoring to optimize dosing and track outcomes. The drug created a new revenue stream in a category—CGM use in non-insulin patients—that was previously niche.
Where Everyone Went Wrong: The Adoption Velocity Problem
This is crucial, and it’s the insight that’s genuinely missing from most analyses (including the first few responses in that transcript).
When people talk about “15% adoption versus 40% adoption,” they treat it as though both scenarios are equally likely endpoints. They’re not. They’re fundamentally different worlds because they require fundamentally different things to happen.
Getting to 15% adoption of GLP-1s among the eligible population (roughly 100 million overweight and obese American adults) requires what’s already in motion: manufacturing scale-up, insurance coverage normalization, and patient awareness. It’s a decade-long slog. The current adoption rate—somewhere in the 5-8% range as of mid-2026—has already hit the low-hanging fruit. Getting to 15% means converting the people who’ve heard about the drugs and can access them.
Getting to 40%? That requires a completely different transformation. That’s not just coverage and access. That’s social normalization at the level of statins. That’s generics and biosimilars collapsing the price from $15,000/year to $3,000/year or less. That’s GLP-1 becoming something you stay on for life, not a 2-3 year intervention for serious weight loss.
The speed of that transition matters more than the endpoint.
A slow climb to 40% adoption over 15 years? Companies adapt, margins adjust gradually, labor gets retrained. A fast climb to 25-30% adoption in 3-4 years (driven by genericization)? That’s systemic disruption. That’s stranded assets, margin cliffs, and forced capital reallocation across entire industries.
Nobody’s modeling that velocity variable separately. Everyone’s treating adoption as inevitable and linear when it’s actually constrained and non-linear.
The Actual Revenue Impact: Smaller Than You Think (So Far)
Let’s be honest about what’s measurable right now:
Medical devices: Yes, some real impact here. Sleep apnea equipment volumes are under pressure, though it’s subtle and offset by new monitoring revenue streams. This is the most documented disruption.
Food and beverage: Strategy shift, not revenue cliff. PepsiCo and Yum Brands are both aggressively repositioning product lines toward lower-calorie and higher-margin formats. But they’re not reporting GLP-1 as a discrete revenue headwind in their filings. They’re treating it as part of a broader wellness trend they were already accommodating.
Airlines and apparel: Search recent earnings calls. You won’t find executives talking about GLP-1 revenue impact. The weight reduction from GLP-1 use might save some fuel costs for airlines, and it might shrink demand for larger clothing sizes, but these effects either don’t show up in financial reporting or are too diffuse to isolate. It’s almost certainly not a material line item.
This matters because it tells you something crucial: the financial system hasn’t actually priced in the disruption scenarios yet. Companies are preparing defensively, but they’re not taking real financial hits. That means the real repricing—if it comes—is still ahead.
What Wall Street’s Getting Wrong (In Both Directions)
Start with the overpriced assumption: the speed of retail and restaurant volume decline.
Most bear-case models assume a simple math: fewer calories consumed equals fewer calories sold equals revenue down. That ignores mix-shift. If a restaurant’s customer spends $15 on three indulgent items and instead spends $15 on one premium, health-focused item, the volume is down but the margin might actually be up. PepsiCo is already moving here—investing heavily in functional and premium formats while scaling back mass-market calorie counts.
Now the underpriced assumption: healthcare provider complexity.
This is where the real second-order effects live. As GLP-1 adoption rises, the clinical burden of obesity-related disease shifts. Fewer bariatric surgeries. Fewer diabetic complications requiring hospitalization. Fewer cardiovascular interventions triggered by weight-driven hypertension. Those are actually profitable procedures for hospitals and health systems. Losing that revenue base in a sector that already operates on thin margins (typically 2-4% net margins for hospitals) creates real structural problems.
But here’s what’s underpriced: the offsetting revenue opportunities. Nutrition counseling, digital adherence platforms, remote monitoring with wearables and CGMs, telehealth integration—these are nascent revenue pools that most analyst models treat as immaterial. They’re not zero. They’re just not fully priced in yet.
The Scenario That Actually Matters
Forget 15% versus 40% as binary choices. The real question is: how fast do we hit 25% adoption, and what does the path to genericization look like?
At slow-burn 15% adoption over 10 years: medical device makers adjust, food companies remix portfolios, hospitals maintain cash flow but redeploy resources. It’s manageable. Stocks reprice gradually. Nobody gets hurt badly.
At fast-track 25% adoption over 3-4 years (driven by biosimilar competition collapsing prices): that’s different. Inspire Medical’s revenue assumptions break. Legacy high-volume, low-margin food categories face real margin compression. Hospitals accelerate their shift away from chronic-disease management without yet fully monetizing preventative care infrastructure. You get a window of vulnerability lasting 2-3 years where incumbents are forced to reposition faster than they can move.
The 40% scenario is almost philosophical at that point—it’s not really about whether it happens, but whether it happens slowly enough for the economy to adapt.
What You Actually Need to Know for Your Memo
One: Pull the actual earnings transcripts from ResMed, Inspire Medical, Dexcom, PepsiCo, and Yum. Verify what’s being said, not what analysts claim was said. The devil is in the exact language management uses.
Two: Model adoption velocity as a separate variable from adoption level. A scenario planning matrix with adoption speed on one axis and adoption level on the other will tell a very different story than two endpoint scenarios.
Three: Track leading indicators religiously—CPAP initiation rates, insurance formulary coverage, GLP-1 prescription fill rates, CGM uptake in type 2 non-insulin patients. These lead earnings impact by 12-18 months. They’re where the real signal lives.
Four: The companies best positioned aren’t the ones betting GLP-1 goes away. They’re the ones treating it as permanent infrastructure and building adjacent revenue. Dexcom understood that. ResMed is learning it. The food companies that win will be the ones that successfully premiumize, not the ones that fight the trend.
The Bottom Line
GLP-1s are absolutely reshaping industries. But the reshaping is slower, subtler, and weirdly asymmetric—helping some companies (CGM makers, premium food brands, provider telehealth platforms) while hurting others (bariatric surgeons, high-volume commodity food, legacy sleep-apnea device makers). The financial impact so far is mostly strategic repositioning, not current-quarter revenue cliffs.
Wall Street knows this intellectually. It just hasn’t fully priced it yet because the impact unfolds over years, not quarters.
That’s where the edge is: in understanding that the disruption is real but slower than the headlines suggest, which means the opportunity window for repositioning is still open—but closing.
